Recent advances and future directions in the management of hepatitis C infections

Pharmacology and Therapeutics

Volumn 145, Issue , 2015, Pages 92-102

  Belousova, Victoria ^a   Abd Rabou, Ahmed A ^a,b,c   Mousa, Shaker A ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b NATIONAL RESEARCH CENTRE   (Egypt)

^c Zewail City of Science and Technology   (Egypt)

Author keywords

C prevention; C treatment; C virus; HCV genotypes; Hepatitis; Interferon free regimens; Vaccine

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; DASABUVIR; HEPATITIS C VACCINE; INTERLEUKIN 28B; MERICITABINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; FUSED HETEROCYCLIC RINGS; SULFONAMIDE; URIDINE PHOSPHATE;

ADVERSE DRUG REACTION; AFRICAN AMERICAN; AGE; ALCOHOL CONSUMPTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG COST; DRUG SAFETY; DRUG TREATMENT FAILURE; GENDER; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; LIVER CIRRHOSIS; MIXED INFECTION; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); STEATOSIS; VIRUS LOAD; VIRUS MORPHOLOGY; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; HEPACIVIRUS; TREATMENT FAILURE;

ANIMALS; ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; SULFONAMIDES; TREATMENT FAILURE; URIDINE MONOPHOSPHATE;

EID: 84918801495     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2014.09.002     Document Type: Review

References (100)

1. Y. Abo-zeid, W. Irving, B. Thomson, and M. Garnett Nanoparticle delivery systems for HCV treatment: do nanoparticles avoid uptake by erythrocytes? Viral Hepatitis Congress 2013 September 26-28, 2013; Frankfurt, Germany 2013
2. M.J. Alter, D. Kruszon-Moran, O.V. Nainan, G.M. McQuillan, F. Gao, and L.A. Moyer The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 N Engl J Med 341 1999 556 562
3. L. Alvarez-Lajonchere, N.H. Shoukry, B. Grá, Y. Amador-Cañizares, F. Helle, and N. Bédard Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial J Viral Hepat 16 2009 156 167
4. Y. Amador-Cañizares, G. Martínez-Donato, L. Álvarez-Lajonchere, C. Vasallo, M. Dausá, and D. Aguilar-Noriega HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin World J Gastroenterol 20 2014 148 162
5. American Society for the Study of Liver Diseases and Infectious Disease Society of America Recommendations for testing, managing, and treating hepatitis C Accessible via http://hcvguidelines.org/full-report-view 2013
6. F. Ansaldi, A. Orsi, L. Sticchi, B. Bruzzone, and G. Icardi Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy World J Gastroenterol 20 2014 9633 9652
7. Y. Arase, F. Suzuki, Y. Suzuki, N. Akuta, Y. Kawamura, and M. Kobayashi Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C Intern Med 46 2007 1827 1832
8. T. Asselah, Y. Benhamou, and P. Marcellin Protease and polymerase inhibitors for the treatment of hepatitis C Liver Int 29 2009 57 67
9. T. Asselah, E. Estrabaud, I. Bieche, M. Lapalus, S. De Muynck, and M. Vidaud Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin Liver Int 30 2010 1259 1269
10. R. Bartenschlager, and V. Lohmann Replication of hepatitis C virus J Gen Virol 81 2000 1631 1648
11. B.E. Behairy, M.A. Saber, I.A. Elhenawy, S.S. Abou-Zeinah, A.A. El-Sharawy, and M.M. Sira Serum cystatin C correlates negatively with viral load in treatment-naïve children with chronic hepatitis C J Pediatr Gastroenterol Nutr 54 2012 364 368
12. G. Bezemer, A.R. Van Gool, E. Verheij-Hart, B.E. Hansen, Y. Lurie, and J.I. Esteban Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study BMC Gastroenterol 12 2012 11
13. M. Bourlière, A. Wendt, H. Fontaine, C. Hézode, S. Pol, and J.P. Bronowicki How to optimize HCV therapy in genotype 1 patients with cirrhosis Liver Int 33 2013 46 55
14. J. Bukh, T. Pietschmann, V. Lohmann, N. Krieger, K. Faulk, and R. Engle Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees Proc Natl Acad Sci U S A 99 2002 14416 14421
15. M.C.B. Castilho, A.N. Martins, I.S. Horbach, R.d.M. Perez, F.A.F. Figueiredo, and P.d.T.A. Pinto, Association of hepatitis C virus NS5B variants with resistance to new antiviral drugs among untreated patients Mem Inst Oswaldo Cruz 106 2011 968 975
16. Centers for Disease Control and Prevention CDC Health Information for International Travel 2014 Accessible via http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-c 2014
17. Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, and M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome Science 244 1989 359 362
18. V.C. Clark, J.A. Peter, and D.R. Nelson New therapeutic strategies in HCV: second-generation protease inhibitors Liver Int 33 2013 80 84
19. Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Surveillance for viral hepatitis - United States, 2011 Accessible via http://www.cdc.gov/hepatitis/Statistics/2011Surveillance/index.htm 2011
20. X. Forns, J. Bukh, and R.H. Purcell The challenge of developing a vaccine against hepatitis C virus J Hepatol 37 2002 684 695
21. A. Fournillier, L. Frelin, E. Jacquier, G. Ahlén, A. Brass, and E. Gerossier A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus J Infect Dis 208 2013 1008 1019
22. E. Foy, K. Li, C. Wang, R. Sumpter Jr., M. Ikeda, and S.M. Lemon Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease Science 300 2003 1145 1148
23. S. Franco, M. Casadellà, M. Noguera-Julian, B. Clotet, C. Tural, and R. Paredes No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing J Clin Virol 58 2013 726 729
24. S.E. Frey, M. Houghton, S. Coates, S. Abrignani, D. Chien, and D. Rosa Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults Vaccine 28 2010 6367 6373
25. R.A. Fridell, D. Qiu, L. Valera, C. Wang, R.E. Rose, and M. Gao Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 J Virol 85 2011 7312 7320
26. M.W. Fried, M. Buti, G.J. Dore, R. Flisiak, P. Ferenci, and I. Jacobson Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study Hepatology 58 2013 1918 1929
27. M.W. Fried, S.J. Hadziyannis, M.L. Shiffman, D. Messinger, and S. Zeuzem Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection J Hepatol 55 2011 69 75
28. E.J. Gane, C.A. Stedman, R.H. Hyland, X. Ding, E. Svarovskaia, and W.T. Symonds Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C N Engl J Med 368 2013 34 44
29. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 65 2010 96 100
30. Gilead Sciences, Inc. SOVALDI full prescribing information Accessible via http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf 2013
31. Gilead Sciences, Inc. U.S. Food and Drug Administration approves Gilead's Sovaldi™ (sofosbuvir) for the treatment of chronic hepatitis C Accessible via http://www.gilead.com/news/press-releases/2013/12/us-food-and-drug-administration-approves-gileads-sovaldi-sofosbuvir-for-the-treatment-of-chronic-hepatitis-c#sthash.uKOXItHl.dpuf 2013
32. J.A. Hubbell Tissue and cell engineering Curr Opin Biotechnol 15 2004 381 382
33. C. Humer Vertex to end sales of hepatitis C drug Incivek Accessible via http://www.reuters.com/article/2014/08/13/us-vertex-hepatitisc-idUSKBN0GD1S520140813 2014
34. P.P. Ip, A. Boerma, J. Regts, T. Meijerhof, J. Wilschut, and H.W. Nijman Alphavirus-based vaccines encoding nonstructural proteins of hepatitis C virus induce robust and protective T-cell responses Mol Ther 22 2014 881 890
35. I.M. Jacobson, G.J. Dore, G. Foster, M.W. Fried, M.N. Radu, and V.V. Rafalskiy Sa2072 simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial Gastroenterology 144 2013 S-374
36. I.M. Jacobson, S.C. Gordon, K.V. Kowdley, E.M. Yoshida, M. Rodriguez-Torres, and M.S. Sulkowski Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options N Engl J Med 368 2013 1867 1877
37. Janssen Therapeutics OLYSIO prescribing information Accessible via http://www.olysio.com/shared/product/olysio/prescribing-information.pdf 2013
38. K.-A. Kim Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin Korean J Hepatol 17 2011 84 86
39. R.M. Klevens, D.J. Hu, R. Jiles, and S.D. Holmberg Evolving epidemiology of hepatitis C virus in the United States Clin Infect Dis 55 2012 S3 S9
40. A.A. Kolykhalov, K. Mihalik, S.M. Feinstone, and C.M. Rice Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo J Virol 74 2000 2046 2051
41. K.V. Kowdley, E. Lawitz, I. Crespo, T. Hassanein, M.N. Davis, and M. DeMicco Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial Lancet 381 2013 2100 2107
42. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, and S.K. Young Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients Hepatology 48 2008 1769 1778
43. P.Y. Kwo, and R. Vinayek The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors Gut Liver 5 2011 406 417
44. M.K. Large, D.J. Kittlesen, and Y.S. Hahn Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence J Immunol 162 1999 931 938
45. E. Lawitz, X. Forns, S. Zeuzem, E. Gane, J.-P. Bronowicki, and P. Andreone 869b Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial Gastroenterology 144 2013 S-151
46. E. Lawitz, R. Ghalib, M. Rodriguez-Torres, Z.M. Younossi, A. Corregidor, and I.M. Jacobson Sa2073 SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin (RBV) in HCV GT 1 null responders Gastroenterology 144 2013 S-374 S-375
47. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, and A.M. Sheikh Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial Lancet Infect Dis 13 2013 401 408
48. E. Lawitz, A. Mangia, D. Wyles, M. Rodriguez-Torres, T. Hassanein, and S.C. Gordon Sofosbuvir for previously untreated chronic hepatitis C infection N Engl J Med 368 2013 1878 1887
49. E. Lawitz, F. Poordad, D.M. Brainard, R.H. Hyland, D. An, and W.T. Symonds Sofosbuvir in combination with pegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study 64th Annual Meeting of the American Association for the Study of Liver Diseases, Nov 1-5, 2013; Washington, DC 2013
50. M.-Y. Lee, J.-A. Yang, H.S. Jung, S. Beack, J.E. Choi, and W. Hur Hyaluronic acid-gold nanoparticle/interferon α complex for targeted treatment of hepatitis C virus infection ACS Nano 6 2012 9522 9531
51. O. Lenz, J. de Bruijne, L. Vijgen, T. Verbinnen, C. Weegink, and H. Van Marck Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy Gastroenterology 143 2012 1176 1178 (.e1176)
52. O. Lenz, T. Verbinnen, T.-I. Lin, L. Vijgen, M.D. Cummings, and J. Lindberg In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435 Antimicrob Agents Chemother 54 2010 1878 1887
53. Y. Lin, T. Kwon, J. Polo, Y.-F. Zhu, S. Coates, and K. Crawford Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5 J Virol 82 2008 7492 7503
54. V. Lohmann, F. Körner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 285 1999 110 113
55. K.N. Ly, J. Xing, R.M. Klevens, R.B. Jiles, J.W. Ward, and S.D. Holmberg The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007 Ann Intern Med 156 2012 271 278
56. A. Macdonald, and M. Harris Hepatitis C virus NS5A: tales of a promiscuous protein J Gen Virol 85 2004 2485 2502
57. M. Makimura, S. Miyake, N. Akino, K. Takamori, Y. Matsuura, and T. Miyamura Induction of antibodies against structural proteins of hepatitis C virus in mice using recombinant adenovirus Vaccine 14 1996 28 34
58. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, and R. Reindollar Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
59. M.P. Manns, H. Reesink, T. Berg, G. Dusheiko, R. Flisiak, and P. Marcellin Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial Antivir Ther 16 2011 1021 1033
60. M.P. Manns, and T. von Hahn Novel therapies for hepatitis C - one pill fits all? Nat Rev Drug Discov 12 2013 595 610
61. M.M. Manos, V.A. Shvachko, R.C. Murphy, J.M. Arduino, and N.J. Shire Distribution of hepatitis C virus genotypes in a diverse US integrated health care population J Med Virol 84 2012 1744 1750
62. O.V. Masalova, E.I. Lesnova, V.V. GrabovetskiÄ, O.A. Smirnova, T.I. Ulanova, and A.N. Burkov DNA immunization with a plasmid containing gene of hepatitis C virus protein 5A (NS5A) induces the effective cellular immune response Mol Biol 44 2010 275 283
63. S. Maylin, M. Martinot-Peignoux, M.P. Ripault, R. Moucari, A.C. Cardoso, and N. Boyer Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody Liver Int 29 2009 511 517
64. J.A. Mira, B. Valera-Bestard, A. Arizcorreta-Yarza, M. González-Serrano, J. Torre-Cisneros, and I. Santos Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients Antivir Ther 12 2007 523 529
65. K. Mohd Hanafiah, J. Groeger, A.D. Flaxman, and S.T. Wiersma Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 57 2013 1333 1342
66. C. Moreno, T. Berg, T. Tanwandee, S. Thongsawat, H. Van Vlierberghe, and S. Zeuzem Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study J Hepatol 56 2012 1247 1253
67. M. Núñez, C. Miralles, M.A. Berdún, E. Losada, K. Aguirrebengoa, and A. Ocampo Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial AIDS Res Hum Retroviruses 23 2007 972 982
68. A. Osinusi, E.G. Meissner, Y.J. Lee, D. Bon, L. Heytens, and A. Nelson Sofosbuvir and ribavirin for hepatitis c genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial JAMA 310 2013 804 811
69. N. Palanisamy, A. Danielsson, C. Kokkula, H. Yin, K. Bondeson, and L. Wesslén Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in hepatitis C virus genotypes 1a, 2b and 3a Antiviral Res 99 2013 12 17
70. C. Park, S. Jiang, and K.A. Lawson Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis J Clin Pharm Ther 39 2014 14 24
71. J.H. Park, S. Lee, J.-H. Kim, K. Park, K. Kim, and I.C. Kwon Polymeric nanomedicine for cancer therapy Prog Polym Sci 33 2008 113 137
72. B.L. Pearlman, and N. Traub Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more Clin Infect Dis 52 2011 889 900
73. F. Poordad, M.P. Manns, P. Marcellin, E.S.A. de Araujo, M. Buti, and Y. Horsmans Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial Gastroenterology 144 2013 S-151
74. C.T. Ranjith-Kumar, and C. Cheng Kao Biochemical activities of the HCV NS5B RNA-dependent RNA polymerase S.L. Tan, Hepatitis C Viruses: Genomes and Molecular Biology 2006 Horizon Bioscience Norfolk (UK)
75. H. Razavi, A.C. ElKhoury, E. Elbasha, C. Estes, K. Pasini, and T. Poynard Chronic hepatitis C virus (HCV) disease burden and cost in the United States Hepatology 57 2013 2164 2170
76. B.M. Rothen-Rutishauser, S. Schürch, B. Haenni, N. Kapp, and P. Gehr Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques Environ Sci Tech 40 2006 4353 4359
77. R. Schekman, and S.J. Singer Clustering and endocytosis of membrane receptors can be induced in mature erythrocytes of neonatal but not adult humans Proc Natl Acad Sci U S A 73 1976 4075 4079
78. R. Schinazi, P. Halfon, P. Marcellin, and T. Asselah HCV direct-acting antiviral agents: the best interferon-free combinations Liver Int 34 2014 69 78
79. S.K. Shoo, and S. Parveen The present and future of nanotechnology in human health care Nanotechnology 3 2007 20 31
80. E. Silverman From riches to rags: vertex discontinues Incivek as sales evaporate Accessible via http://blogs.wsj.com/pharmalot/2014/08/12/from-riches-to-rags-vertex-discontinues-incivek-as-sales-evaporate/ 2014
81. X. Simin, S. Rajyaguru, S. Chiu, C. Hebner, E.S. Svarovskaia, and V. Gontcharova Sofosbuvir selects the NS5B S282T mutation in vitro in genotype 1-6 replicons and is not cross-resistant to resistance-associated variants selected by other classes of antiviral inhibitors 64th Annual Meeting of the American Association for the Study of Liver Diseases Nov 1-5, 2013 Washington, DC
82. P. Simmonds Genetic diversity and evolution of hepatitis C virus - 15 years on J Gen Virol 85 2004 3173 3188
83. Z. Stamataki, S. Coates, S. Abrignani, M. Houghton, and J.A. McKeating Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains J Infect Dis 204 2011 811 813
84. M.S. Sulkowski, D.F. Gardiner, M. Rodriguez-Torres, K.R. Reddy, T. Hassanein, and I. Jacobson Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N Engl J Med 370 2014 211 221
85. B. Sumer, and J. Gao Therapeutic nanomedicine for cancer J Nanomed 3 2008 137 140
86. S. Susser, J. Vermehren, N. Forestier, M.W. Welker, N. Grigorian, and C. Füller Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir J Clin Virol 52 2011 321 327
87. E.S. Svarovskaia, H.S. Dvory-Sobol, C. Hebner, B. Doehle, V. Gontcharova, and R. Martin No resistance detected in four phase 3 clinical studies in HCV genotypes 1-6 of sofosbuvir + ribavirin with or without peginterferon 64th Annual Meeting of the American Association for the Study of Liver Diseases, Nov 1-5, 2013; Washington, DC 2013
88. M.G. Swain, M.Y. Lai, M.L. Shiffman, W.G.E. Cooksley, S. Zeuzem, and D.T. Dieterich A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin Gastroenterology 139 2010 1593 1601
89. X. Tong, S. Le Pogam, L. Li, K. Haines, K. Piso, and V. Baronas In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir J Infect Dis 209 2014 668 675
90. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh, E. Lissen, J. Gonzalez-García, and A. Lazzarin Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
91. M. Trapero-Marugán, J. Mendoza, M. Chaparro, L. González-Moreno, J.A. Moreno-Monteagudo, and M.J. Borque Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin World J Gastroenterol 17 2011 493 498
92. S. Ullah, M.A.A. Shah, and N. Riaz Recent advances in development of DNA vaccines against hepatitis C virus Indian J Virol 23 2012 253 260
93. C. Wang, L. Jia, H. Huang, D. Qiu, L. Valera, and X. Huang In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A Antimicrob Agents Chemother 56 2012 1588 1590
94. C. Wang, L. Valera, L. Jia, M.J. Kirk, M. Gao, and R.A. Fridell In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A Antimicrob Agents Chemother 57 2013 611 613
95. World Health Organization Global Alert and Response (GAR), hepatitis C Accessible via http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index2.html 2002
96. J.-W. Youn, Y.-W. Hu, N. Tricoche, W. Pfahler, M.T. Shata, and M. Dreux Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus J Virol 82 2008 10896 10905
97. S. Zeuzem, T. Berg, E. Gane, P. Ferenci, G.R. Foster, and M.W. Fried Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial Gastroenterology 146 2014 430 441 (.e436)
98. S. Zeuzem, G.M. Dusheiko, R. Salupere, A. Mangia, R. Flisiak, and R.H. Hyland Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial 64th Annual Meeting of the American Association for the Study of Liver Diseases, Nov 1-5, 2013; Washington, DC 2013
99. Y. Zhu, and S. Chen Antiviral treatment of hepatitis C virus infection and factors affecting efficacy World J Gastroenterol 19 2013 8963 8973
100. A. Zidan, H. Scheuerlein, S. Schüle, U. Settmacher, and F. Rauchfuss Epidemiological pattern of hepatitis B and hepatitis C as etiological agents for hepatocellular carcinoma in Iran and worldwide Hepat Mon 12 2012 e6894